John W Kuo Net Worth

The estimated Net Worth of John W Kuo is at least 4.97 百万$ dollars as of 18 February 2020. John Kuo owns over 2,601 units of Varian Medical Systems stock worth over 680,581$ and over the last 19 years John sold VAR stock worth over 4,286,402$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Kuo VAR stock SEC Form 4 insiders trading

John has made over 82 trades of the Varian Medical Systems stock since 2011, according to the Form 4 filled with the SEC. Most recently John exercised 2,601 units of VAR stock worth 43,008$ on 18 February 2020.

The largest trade John's ever made was exercising 57,778 units of Varian Medical Systems stock on 22 December 2011 worth over 2,880,811$. On average, John trades about 2,192 units every 22 days since 2005. As of 18 February 2020 John still owns at least 41,160 units of Varian Medical Systems stock.

You can see the complete history of John Kuo stock trades at the bottom of the page.

Insiders trading at Varian Medical Systems

Over the last 22 years, insiders at Varian Medical Systems have traded over 57,574,967$ worth of Varian Medical Systems stock and bought 500 units worth 22,595$ . The most active insiders traders include Kent J Thiry、Timothy E Guertin、Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of 181,124$. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth 1,142,589$.

What does Varian Medical Systems do?

Complete history of John Kuo stock trades at Charles River Laboratories International、Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys